Table 3.
Results related to treatments to be prescribed in T2T strategy on osteoporosis
| Question | Wish (%) | Prognosis (%) | ||||
|---|---|---|---|---|---|---|
| A | I | D | A | I | D | |
| The T2T strategy in osteoporosis is possible with the following anti-osteoporotic treatment: | ||||||
| a. oral bisphosphonates | 88.4 | 5.4 | 6.3 | 88.4 | 3.6 | 8.0 |
| b. intravenous bisphosphonates | 92.0 | 6.3 | 1.8 | 89.3 | 6.3 | 4.5 |
| c. SERM | 94.3 | 1.9 | 3.8 | 96.2 | – | 3.8 |
| d. strontium ranelate | 76.4 | 5.7 | 17.9 | 58.5 | 4.7 | 36.8 |
| e. denosumab | 97.3 | 1.8 | 0.9 | 94.6 | 3.6 | 1.8 |
| f. teriparatide | 96.4 | 1.8 | 1.8 | 92.0 | 4.5 | 3.6 |
| g. denosumab plus teriparatide | 80.4 | 11.6 | 8.0 | 78.6 | 10.7 | 10.7 |
| h. developing treatments | 86.6 | 11.6 | 1.8 | 81.3 | 13.4 | 5.4 |
| In patients treated with bisphosphonates, once the therapeutic objective has been reached, the treatment has to be | ||||||
| a. stopped for a period of time (drug holiday) | 81.3 | 2.7 | 16.1 | 77.7 | 6.3 | 16.1 |
| b. continued indefinitely | 12.5 | 1.8 | 85.7 | 10.7 | 9.8 | 79.5 |
| c. switched | 5.7 | 1.9 | 92.5 | 5.7 | 1.9 | 92.5 |
| In patients treated with SERM, once the therapeutic objective has been reached, the treatment has to be | ||||||
| a. stopped for a period of time (drug holiday) | 34.0 | 3.8 | 62.3 | 36.8 | 4.7 | 8.5 |
| b. continued indefinitely | 16.1 | 7.1 | 76.8 | 17.0 | 8.0 | 75.0 |
| c. switched | 32.1 | 4.7 | 63.2 | 26.4 | 7.5 | 66.0 |
| In patients treated with strontium ranelate, once the therapeutic objective has been reached, the treatment has to be | ||||||
| a. stopped for a period of time (drug holiday) | 84.0 | 7.5 | 8.5 | 83.0 | 8.5 | 8.5 |
| b. continued indefinitely | 8.9 | 8.0 | 83.0 | 8.9 | 10.7 | 80.4 |
| c. switched | 67.9 | 6.6 | 25.5 | 68.9 | 6.6 | 24.5 |
| In patients treated with teriparatide, once the therapeutic objective has been reached, the treatment has to be | ||||||
| a. stopped for a period of time (drug holiday) | 75.5 | 1.9 | 22.6 | 76.4 | 1.9 | 21.7 |
| b. continued indefinitely | 3.6 | 2.7 | 93.8 | 2.7 | 4.5 | 92.9 |
| c. switched | 80.4 | 3.6 | 16.1 | 77.7 | 5.4 | 17.0 |
| In patients treated with denosumab, once the therapeutic objective has been reached, the treatment has to be | ||||||
| a. stopped for a period of time (drug holiday) | 81.1 | – | 18.9 | 84.9 | – | 15.1 |
| b. continued indefinitely | 8.5 | – | 91.5 | 6.6 | 0.9 | 92.5 |
| c. switched | 15.1 | 2.8 | 82.1 | 12.3 | 3.8 | 84.0 |
Italic values represent the most answered option
A agreement, I indifference, D disagreement, wish (desire for it to happen), prognosis (belief that it will happen in a 5-year period)